Silo Pharma to Present at the Dawson James Small Cap Growth Conference on October 12
Silo Pharma, Inc. (Nasdaq: SILO) will present at the 7th Annual Dawson James Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Silo Pharma, Inc. (Nasdaq: SILO) will present at the 7th Annual Dawson James Small Cap Growth Conference on October 12, 2022, in Jupiter, Florida. CEO Eric Weisblum will discuss the company's novel therapeutic candidates, emphasizing its collaboration with renowned academic institutions. The presentation will cover Silo's innovative approach in merging traditional therapeutics with psychedelic research, targeting conditions like Alzheimer’s, multiple sclerosis, and mental health disorders. A live webcast will be available, along with a replay for 90 days on the company’s investors site.
Details
News Market Reaction – SILO
The recorded move for SILO in the trading session of this news was -1.67%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Presentation to feature Company’s novel therapeutic candidates under development in collaboration with leading academic institutions
ENGLEWOOD CLIFFS, NJ, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that CEO Eric Weisblum will present and host investor meetings at the 7th Annual Dawson James Small Cap Growth Conference being held Wednesday, October 12, 2022, at the Wyndham Grand Hotel in Jupiter, Florida.
Presentation:
- The Company’s presentation will be available for viewing live on October 12 via webcast.
- Please consult the conference website for the presentation time.
- A webcast replay will be available for the following 90 days on the Company’s Investors website.
One-on-one Meetings:
- To request a meeting with Mr. Weisblum, please contact your Dawson James representative.
At the conference, Mr. Weisblum will discuss Silo Pharma’s acquisition and development of intellectual property and technology rights from leading universities and researchers, including the use of the psychedelic drugs. He will also discus the Company’s diversified pipeline showing promise in underserved rare disease, neurological, and mental health indications. These therapeutics are currently under development for the treatment of Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis, stress-induced psychiatric disorders, and fibromyalgia.
About Silo Pharma
Silo Pharma. Inc. is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzhiemer’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the healthcare industry. For more information, visit www.silopharma.com
Contact
800-705-0120
investors@silopharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.